Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 17/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | ABL2 | P42684 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15345471 | 1.00 | FGFR2 (0.63) | FGFR2SRCABL1EGFRABL2 | |
| SCHEMBL15345540 | 0.92 | FGFR2 (0.65) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL30291139 | 0.81 | FGFR2 (0.63) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345414 | 0.81 | FGFR2 (0.63) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345411 | 0.81 | FGFR2 (0.63) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345778 | 0.80 | FGFR2 (0.63) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345516 | 0.79 | FGFR2 (0.62) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345515 | 0.79 | FGFR2 (0.62) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL27980322 | 0.79 | FGFR2 (0.57) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15345690 | 0.78 | FGFR2 (0.69) | FGFR2FGFR1FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| EP-3023101-B1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3023100-B1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-17 | — | — | US | disclosed |
| US-10124003-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-3023100-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023101-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| CN-103958512-B | The two substituted alkynyl benzene compound of 3,5-and salt thereof | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| US-9108973-B2 | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2657233-B1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| CN-103958512-A | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO LTD | 2014-07-30 | — | — | CN | disclosed |
| EP-2657233-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | FGFR2 3/4885SRC 54/4885ABL1 19/4885 |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | FGFR2 4/4885SRC 48/4885ABL1 31/4885 |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | FGFR2 4/4885SRC 48/4885ABL1 31/4885 |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | FGFR2 3/4885SRC 35/4885ABL1 12/4885 |
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | FGFR1, FGFR3, FGFR2 | FGFR2 3/4885SRC 54/4885ABL1 19/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | FGFR2 1329/4885SRC 306/4885ABL1 13/4885 |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | FGFR2 4/4885SRC 48/4885ABL1 31/4885 |
| US-10124003-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | FGFR2 4/4885SRC 48/4885ABL1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.